Review



biotinylated detection antibody  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 85
      Buy from Supplier

    Structured Review

    R&D Systems biotinylated detection antibody
    Biotinylated Detection Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 85/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+osm/Human+Oncostatin+M%2FOSM+Biotinylated+Antibody/pm41595754-60-44-52
    Average 85 stars, based on 2 article reviews
    biotinylated detection antibody - by Bioz Stars, 2026-09
    85/100 stars

    Images

    Related Articles

    Injection:

    Article Title: Skin basal cell carcinomas assemble a pro-tumorigenic spatially organized and self-propagating Trem2+ myeloid niche
    Article Snippet: .. Once the tumors were palpable, measurements were made, and mice were then injected with 20 μg of anti-Osm (R&D; AF-495-NA) or anti-IgG (BioXCell; BP0086) antibody for three initial days, followed by every other day for seven total injections. ..

    Immunofluorescence:

    Article Title: Oncostatin M is overexpressed in skin squamous-cell carcinoma and promotes tumor progression
    Article Snippet: .. For immunofluorescence studies, tumor sections were fixed in acetone/methanol (20/80) and stained with anti-OSM (R&D system, MAB4951, 1:50), followed by staining with a goat anti-rat-IgGAF555 secondary antibody (Thermofisher, A-21434, 1:100). .. Cell nuclei were stained with TOPRO (Invitrogen).

    Staining:

    Article Title: Oncostatin M is overexpressed in skin squamous-cell carcinoma and promotes tumor progression
    Article Snippet: .. For immunofluorescence studies, tumor sections were fixed in acetone/methanol (20/80) and stained with anti-OSM (R&D system, MAB4951, 1:50), followed by staining with a goat anti-rat-IgGAF555 secondary antibody (Thermofisher, A-21434, 1:100). .. Cell nuclei were stained with TOPRO (Invitrogen).

    Article Title: Toll-Like Receptor 2 Stimulation of Osteoblasts Mediates Staphylococcus Aureus Induced Bone Resorption and Osteoclastogenesis through Enhanced RANKL
    Article Snippet: .. Essentially fatty acid-free bovine serum albumin (BSA), tartrate-resistant acid phosphatase (TRAP) staining-kit (Sigma-Aldrich); alpha minimum essential medium (α-MEM), zoledronic acid, and indomethacin (Invitrogen); [ 45 Ca]CaCl 2 (Amersham Biosciences); oligonucleotide primers and probes, L-glutamine (Invitrogen or Applied Biosystems); TLR2 agonist (Palmitoyl-2-Cys-Ser-(Lys) 4 ) Pam2, lipoprotein-containing lipopolysaccharide from Porphyromonas gingivalis (LPS P . gingivalis ), heat killed Listeria Monocytogenes (HKLM) (InvivoGen); antibiotics (AstraZeneca); culture dishes, multiwell plates (Nunc Inc.); mouse recombinant OPG, RANKL, M-CSF, IL-1β, IL-6, IL-6sR, IL-11, oncostatin (OSM), leukemia inhibitory factor (LIF), tumor necrosis factor-α (TNF-α), anti-IL-1β (MAB401), anti-IL-6 (MAP406), anti-IL-11 (AF 418 NA), anti-OSM (AF 495 NA), anti-LIF (AF 449), anti-TNF-α (MAB 4101) (R&D Systems); RatLaps TM CTX ELISA kit (Immonodiagnosticsystems); Prostaglandin E 2 [ 125 I]-RIA ® Kit (Perkin-Elmer); RNAqueous–4 PCR ® kit (Ambion); High-Capacity cDNA Reverse Transcription ® Kit (Applied Biosystems); Kapa2G TM Robust HotStart PCR kit, Kapa TM Probe Fast qPCR kit (KapaBiosystems). ..

    Recombinant:

    Article Title: Toll-Like Receptor 2 Stimulation of Osteoblasts Mediates Staphylococcus Aureus Induced Bone Resorption and Osteoclastogenesis through Enhanced RANKL
    Article Snippet: .. Essentially fatty acid-free bovine serum albumin (BSA), tartrate-resistant acid phosphatase (TRAP) staining-kit (Sigma-Aldrich); alpha minimum essential medium (α-MEM), zoledronic acid, and indomethacin (Invitrogen); [ 45 Ca]CaCl 2 (Amersham Biosciences); oligonucleotide primers and probes, L-glutamine (Invitrogen or Applied Biosystems); TLR2 agonist (Palmitoyl-2-Cys-Ser-(Lys) 4 ) Pam2, lipoprotein-containing lipopolysaccharide from Porphyromonas gingivalis (LPS P . gingivalis ), heat killed Listeria Monocytogenes (HKLM) (InvivoGen); antibiotics (AstraZeneca); culture dishes, multiwell plates (Nunc Inc.); mouse recombinant OPG, RANKL, M-CSF, IL-1β, IL-6, IL-6sR, IL-11, oncostatin (OSM), leukemia inhibitory factor (LIF), tumor necrosis factor-α (TNF-α), anti-IL-1β (MAB401), anti-IL-6 (MAP406), anti-IL-11 (AF 418 NA), anti-OSM (AF 495 NA), anti-LIF (AF 449), anti-TNF-α (MAB 4101) (R&D Systems); RatLaps TM CTX ELISA kit (Immonodiagnosticsystems); Prostaglandin E 2 [ 125 I]-RIA ® Kit (Perkin-Elmer); RNAqueous–4 PCR ® kit (Ambion); High-Capacity cDNA Reverse Transcription ® Kit (Applied Biosystems); Kapa2G TM Robust HotStart PCR kit, Kapa TM Probe Fast qPCR kit (KapaBiosystems). ..

    Enzyme-linked Immunosorbent Assay:

    Article Title: Toll-Like Receptor 2 Stimulation of Osteoblasts Mediates Staphylococcus Aureus Induced Bone Resorption and Osteoclastogenesis through Enhanced RANKL
    Article Snippet: .. Essentially fatty acid-free bovine serum albumin (BSA), tartrate-resistant acid phosphatase (TRAP) staining-kit (Sigma-Aldrich); alpha minimum essential medium (α-MEM), zoledronic acid, and indomethacin (Invitrogen); [ 45 Ca]CaCl 2 (Amersham Biosciences); oligonucleotide primers and probes, L-glutamine (Invitrogen or Applied Biosystems); TLR2 agonist (Palmitoyl-2-Cys-Ser-(Lys) 4 ) Pam2, lipoprotein-containing lipopolysaccharide from Porphyromonas gingivalis (LPS P . gingivalis ), heat killed Listeria Monocytogenes (HKLM) (InvivoGen); antibiotics (AstraZeneca); culture dishes, multiwell plates (Nunc Inc.); mouse recombinant OPG, RANKL, M-CSF, IL-1β, IL-6, IL-6sR, IL-11, oncostatin (OSM), leukemia inhibitory factor (LIF), tumor necrosis factor-α (TNF-α), anti-IL-1β (MAB401), anti-IL-6 (MAP406), anti-IL-11 (AF 418 NA), anti-OSM (AF 495 NA), anti-LIF (AF 449), anti-TNF-α (MAB 4101) (R&D Systems); RatLaps TM CTX ELISA kit (Immonodiagnosticsystems); Prostaglandin E 2 [ 125 I]-RIA ® Kit (Perkin-Elmer); RNAqueous–4 PCR ® kit (Ambion); High-Capacity cDNA Reverse Transcription ® Kit (Applied Biosystems); Kapa2G TM Robust HotStart PCR kit, Kapa TM Probe Fast qPCR kit (KapaBiosystems). ..

    Polymerase Chain Reaction:

    Article Title: Toll-Like Receptor 2 Stimulation of Osteoblasts Mediates Staphylococcus Aureus Induced Bone Resorption and Osteoclastogenesis through Enhanced RANKL
    Article Snippet: .. Essentially fatty acid-free bovine serum albumin (BSA), tartrate-resistant acid phosphatase (TRAP) staining-kit (Sigma-Aldrich); alpha minimum essential medium (α-MEM), zoledronic acid, and indomethacin (Invitrogen); [ 45 Ca]CaCl 2 (Amersham Biosciences); oligonucleotide primers and probes, L-glutamine (Invitrogen or Applied Biosystems); TLR2 agonist (Palmitoyl-2-Cys-Ser-(Lys) 4 ) Pam2, lipoprotein-containing lipopolysaccharide from Porphyromonas gingivalis (LPS P . gingivalis ), heat killed Listeria Monocytogenes (HKLM) (InvivoGen); antibiotics (AstraZeneca); culture dishes, multiwell plates (Nunc Inc.); mouse recombinant OPG, RANKL, M-CSF, IL-1β, IL-6, IL-6sR, IL-11, oncostatin (OSM), leukemia inhibitory factor (LIF), tumor necrosis factor-α (TNF-α), anti-IL-1β (MAB401), anti-IL-6 (MAP406), anti-IL-11 (AF 418 NA), anti-OSM (AF 495 NA), anti-LIF (AF 449), anti-TNF-α (MAB 4101) (R&D Systems); RatLaps TM CTX ELISA kit (Immonodiagnosticsystems); Prostaglandin E 2 [ 125 I]-RIA ® Kit (Perkin-Elmer); RNAqueous–4 PCR ® kit (Ambion); High-Capacity cDNA Reverse Transcription ® Kit (Applied Biosystems); Kapa2G TM Robust HotStart PCR kit, Kapa TM Probe Fast qPCR kit (KapaBiosystems). ..

    Reverse Transcription:

    Article Title: Toll-Like Receptor 2 Stimulation of Osteoblasts Mediates Staphylococcus Aureus Induced Bone Resorption and Osteoclastogenesis through Enhanced RANKL
    Article Snippet: .. Essentially fatty acid-free bovine serum albumin (BSA), tartrate-resistant acid phosphatase (TRAP) staining-kit (Sigma-Aldrich); alpha minimum essential medium (α-MEM), zoledronic acid, and indomethacin (Invitrogen); [ 45 Ca]CaCl 2 (Amersham Biosciences); oligonucleotide primers and probes, L-glutamine (Invitrogen or Applied Biosystems); TLR2 agonist (Palmitoyl-2-Cys-Ser-(Lys) 4 ) Pam2, lipoprotein-containing lipopolysaccharide from Porphyromonas gingivalis (LPS P . gingivalis ), heat killed Listeria Monocytogenes (HKLM) (InvivoGen); antibiotics (AstraZeneca); culture dishes, multiwell plates (Nunc Inc.); mouse recombinant OPG, RANKL, M-CSF, IL-1β, IL-6, IL-6sR, IL-11, oncostatin (OSM), leukemia inhibitory factor (LIF), tumor necrosis factor-α (TNF-α), anti-IL-1β (MAB401), anti-IL-6 (MAP406), anti-IL-11 (AF 418 NA), anti-OSM (AF 495 NA), anti-LIF (AF 449), anti-TNF-α (MAB 4101) (R&D Systems); RatLaps TM CTX ELISA kit (Immonodiagnosticsystems); Prostaglandin E 2 [ 125 I]-RIA ® Kit (Perkin-Elmer); RNAqueous–4 PCR ® kit (Ambion); High-Capacity cDNA Reverse Transcription ® Kit (Applied Biosystems); Kapa2G TM Robust HotStart PCR kit, Kapa TM Probe Fast qPCR kit (KapaBiosystems). ..

    Real-time Polymerase Chain Reaction:

    Article Title: Toll-Like Receptor 2 Stimulation of Osteoblasts Mediates Staphylococcus Aureus Induced Bone Resorption and Osteoclastogenesis through Enhanced RANKL
    Article Snippet: .. Essentially fatty acid-free bovine serum albumin (BSA), tartrate-resistant acid phosphatase (TRAP) staining-kit (Sigma-Aldrich); alpha minimum essential medium (α-MEM), zoledronic acid, and indomethacin (Invitrogen); [ 45 Ca]CaCl 2 (Amersham Biosciences); oligonucleotide primers and probes, L-glutamine (Invitrogen or Applied Biosystems); TLR2 agonist (Palmitoyl-2-Cys-Ser-(Lys) 4 ) Pam2, lipoprotein-containing lipopolysaccharide from Porphyromonas gingivalis (LPS P . gingivalis ), heat killed Listeria Monocytogenes (HKLM) (InvivoGen); antibiotics (AstraZeneca); culture dishes, multiwell plates (Nunc Inc.); mouse recombinant OPG, RANKL, M-CSF, IL-1β, IL-6, IL-6sR, IL-11, oncostatin (OSM), leukemia inhibitory factor (LIF), tumor necrosis factor-α (TNF-α), anti-IL-1β (MAB401), anti-IL-6 (MAP406), anti-IL-11 (AF 418 NA), anti-OSM (AF 495 NA), anti-LIF (AF 449), anti-TNF-α (MAB 4101) (R&D Systems); RatLaps TM CTX ELISA kit (Immonodiagnosticsystems); Prostaglandin E 2 [ 125 I]-RIA ® Kit (Perkin-Elmer); RNAqueous–4 PCR ® kit (Ambion); High-Capacity cDNA Reverse Transcription ® Kit (Applied Biosystems); Kapa2G TM Robust HotStart PCR kit, Kapa TM Probe Fast qPCR kit (KapaBiosystems). ..



    Similar Products

    human oncostatin m/osm antibody  (Bio-Techne corporation)
    94
    Bio-Techne corporation human oncostatin m/osm antibody
    Human Oncostatin M/Osm Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+osm/Human+Oncostatin+M%2FOSM+Antibody/bio-techne+corporation___mab295
    Average 94 stars, based on 1 article reviews
    human oncostatin m/osm antibody - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    biotinylated detection antibody  (R&D Systems)
    85
    R&D Systems biotinylated detection antibody
    Biotinylated Detection Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+osm/Human+Oncostatin+M%2FOSM+Biotinylated+Antibody/pm41595754-60-44-52
    Average 85 stars, based on 1 article reviews
    biotinylated detection antibody - by Bioz Stars, 2026-09
    85/100 stars
    		  Buy from Supplier
    anti mosm antibody  (R&D Systems)
    92
    R&D Systems anti mosm antibody
    Treatment of JAK2 p.V617F + animals with an anti-OSM receptor fusion protein <t>or</t> <t>monoclonal</t> anti-OSM antibody ameliorates polycythemia and osteosclerosis. a Structure of the anti-OSM receptor fusion protein (“anti-OSMR-FP”): the extracellular domains (D) 1–4 of the murine OSMR receptor were fused to D2–3 of murine gp130 and C-terminally Fc- and HA-tagged. , , Figure generated with BioRender. b Outline of the in vivo anti-OSMR-FP treatment: Intraperitoneal injections (6 µg/g body weight) were administered every two days from day 7 posttransplantation and maintained for 30 days in Jak2 p.V617F + BM recipients. N = 5 for each treatment group. c , d Hemoglobin (HGB) in PBS-, control peptide-, and anti-OSMR-FP-treated animals one month after treatment ( c ) and over time ( d ). N = 5 for each treatment group. * p < 0.05. The data are presented as the means ± SEMs. e Assessment of GM-CSF levels via bead-based flow cytometry in mice 10 weeks after BM transplantation. * p < 0.05. f Hematoxylin/eosin staining of bone specimens from JAK2 p.V617F + mice treated with control peptide (left) or anti-OSMR-FP (right). g Osteosclerosis score. N ≥ 4. * p < 0.05. Statistical analysis was conducted via the Mann‒Whitney test. The data are presented as the means ± SEMs. h Outline of the in vivo treatment of mice transplanted with Jak2 p.V617F + BM with a rat-derived monoclonal <t>anti-mOSM</t> antibody (αOSM). Intraperitoneal injections started on day 7 posttransplantation and were administered weekly for a total of four injections. N = 4 for each treatment group. i , j Hemoglobin (HGB) ( i ) and white blood cell count (WBC) ( j ) in isotype- vs. αOSM-treated animals, as assessed one month after BM transplantation. N = 4 vs. 4. * p < 0.05. The data are presented as the means ± SEMs. k Evaluation of GM-CSF levels on day 80 posttransplantation via bead-based flow cytometry. * p < 0.05. The data are presented as the means ± SEMs
    Anti Mosm Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+osm/Mouse+Oncostatin+M%2FOSM+Antibody/pmc12696130-365-10-13
    Average 92 stars, based on 1 article reviews
    anti mosm antibody - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier
    osm  (Bioss)
    94
    Bioss osm
    Treatment of JAK2 p.V617F + animals with an anti-OSM receptor fusion protein <t>or</t> <t>monoclonal</t> anti-OSM antibody ameliorates polycythemia and osteosclerosis. a Structure of the anti-OSM receptor fusion protein (“anti-OSMR-FP”): the extracellular domains (D) 1–4 of the murine OSMR receptor were fused to D2–3 of murine gp130 and C-terminally Fc- and HA-tagged. , , Figure generated with BioRender. b Outline of the in vivo anti-OSMR-FP treatment: Intraperitoneal injections (6 µg/g body weight) were administered every two days from day 7 posttransplantation and maintained for 30 days in Jak2 p.V617F + BM recipients. N = 5 for each treatment group. c , d Hemoglobin (HGB) in PBS-, control peptide-, and anti-OSMR-FP-treated animals one month after treatment ( c ) and over time ( d ). N = 5 for each treatment group. * p < 0.05. The data are presented as the means ± SEMs. e Assessment of GM-CSF levels via bead-based flow cytometry in mice 10 weeks after BM transplantation. * p < 0.05. f Hematoxylin/eosin staining of bone specimens from JAK2 p.V617F + mice treated with control peptide (left) or anti-OSMR-FP (right). g Osteosclerosis score. N ≥ 4. * p < 0.05. Statistical analysis was conducted via the Mann‒Whitney test. The data are presented as the means ± SEMs. h Outline of the in vivo treatment of mice transplanted with Jak2 p.V617F + BM with a rat-derived monoclonal <t>anti-mOSM</t> antibody (αOSM). Intraperitoneal injections started on day 7 posttransplantation and were administered weekly for a total of four injections. N = 4 for each treatment group. i , j Hemoglobin (HGB) ( i ) and white blood cell count (WBC) ( j ) in isotype- vs. αOSM-treated animals, as assessed one month after BM transplantation. N = 4 vs. 4. * p < 0.05. The data are presented as the means ± SEMs. k Evaluation of GM-CSF levels on day 80 posttransplantation via bead-based flow cytometry. * p < 0.05. The data are presented as the means ± SEMs
    Osm, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+osm/Oncostatin+M+Polyclonal+Antibody/pm41299205-94-25-28
    Average 94 stars, based on 1 article reviews
    osm - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    anti human osm antibody  (R&D Systems)
    93
    R&D Systems anti human osm antibody
    Treatment of JAK2 p.V617F + animals with an anti-OSM receptor fusion protein <t>or</t> <t>monoclonal</t> anti-OSM antibody ameliorates polycythemia and osteosclerosis. a Structure of the anti-OSM receptor fusion protein (“anti-OSMR-FP”): the extracellular domains (D) 1–4 of the murine OSMR receptor were fused to D2–3 of murine gp130 and C-terminally Fc- and HA-tagged. , , Figure generated with BioRender. b Outline of the in vivo anti-OSMR-FP treatment: Intraperitoneal injections (6 µg/g body weight) were administered every two days from day 7 posttransplantation and maintained for 30 days in Jak2 p.V617F + BM recipients. N = 5 for each treatment group. c , d Hemoglobin (HGB) in PBS-, control peptide-, and anti-OSMR-FP-treated animals one month after treatment ( c ) and over time ( d ). N = 5 for each treatment group. * p < 0.05. The data are presented as the means ± SEMs. e Assessment of GM-CSF levels via bead-based flow cytometry in mice 10 weeks after BM transplantation. * p < 0.05. f Hematoxylin/eosin staining of bone specimens from JAK2 p.V617F + mice treated with control peptide (left) or anti-OSMR-FP (right). g Osteosclerosis score. N ≥ 4. * p < 0.05. Statistical analysis was conducted via the Mann‒Whitney test. The data are presented as the means ± SEMs. h Outline of the in vivo treatment of mice transplanted with Jak2 p.V617F + BM with a rat-derived monoclonal <t>anti-mOSM</t> antibody (αOSM). Intraperitoneal injections started on day 7 posttransplantation and were administered weekly for a total of four injections. N = 4 for each treatment group. i , j Hemoglobin (HGB) ( i ) and white blood cell count (WBC) ( j ) in isotype- vs. αOSM-treated animals, as assessed one month after BM transplantation. N = 4 vs. 4. * p < 0.05. The data are presented as the means ± SEMs. k Evaluation of GM-CSF levels on day 80 posttransplantation via bead-based flow cytometry. * p < 0.05. The data are presented as the means ± SEMs
    Anti Human Osm Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+osm/Human+Oncostatin+M%2FOSM+Antibody/pm41198931-425-19-22
    Average 93 stars, based on 1 article reviews
    anti human osm antibody - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    anti human osm antibodies  (R&D Systems)
    93
    R&D Systems anti human osm antibodies
    Treatment of JAK2 p.V617F + animals with an anti-OSM receptor fusion protein <t>or</t> <t>monoclonal</t> anti-OSM antibody ameliorates polycythemia and osteosclerosis. a Structure of the anti-OSM receptor fusion protein (“anti-OSMR-FP”): the extracellular domains (D) 1–4 of the murine OSMR receptor were fused to D2–3 of murine gp130 and C-terminally Fc- and HA-tagged. , , Figure generated with BioRender. b Outline of the in vivo anti-OSMR-FP treatment: Intraperitoneal injections (6 µg/g body weight) were administered every two days from day 7 posttransplantation and maintained for 30 days in Jak2 p.V617F + BM recipients. N = 5 for each treatment group. c , d Hemoglobin (HGB) in PBS-, control peptide-, and anti-OSMR-FP-treated animals one month after treatment ( c ) and over time ( d ). N = 5 for each treatment group. * p < 0.05. The data are presented as the means ± SEMs. e Assessment of GM-CSF levels via bead-based flow cytometry in mice 10 weeks after BM transplantation. * p < 0.05. f Hematoxylin/eosin staining of bone specimens from JAK2 p.V617F + mice treated with control peptide (left) or anti-OSMR-FP (right). g Osteosclerosis score. N ≥ 4. * p < 0.05. Statistical analysis was conducted via the Mann‒Whitney test. The data are presented as the means ± SEMs. h Outline of the in vivo treatment of mice transplanted with Jak2 p.V617F + BM with a rat-derived monoclonal <t>anti-mOSM</t> antibody (αOSM). Intraperitoneal injections started on day 7 posttransplantation and were administered weekly for a total of four injections. N = 4 for each treatment group. i , j Hemoglobin (HGB) ( i ) and white blood cell count (WBC) ( j ) in isotype- vs. αOSM-treated animals, as assessed one month after BM transplantation. N = 4 vs. 4. * p < 0.05. The data are presented as the means ± SEMs. k Evaluation of GM-CSF levels on day 80 posttransplantation via bead-based flow cytometry. * p < 0.05. The data are presented as the means ± SEMs
    Anti Human Osm Antibodies, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+osm/Human+Oncostatin+M%2FOSM+Antibody/pm41198931-416-12-15
    Average 93 stars, based on 1 article reviews
    anti human osm antibodies - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    anti osm aabs  (Cell Signaling Technology Inc)
    86
    Cell Signaling Technology Inc anti osm aabs
    Treatment of JAK2 p.V617F + animals with an anti-OSM receptor fusion protein <t>or</t> <t>monoclonal</t> anti-OSM antibody ameliorates polycythemia and osteosclerosis. a Structure of the anti-OSM receptor fusion protein (“anti-OSMR-FP”): the extracellular domains (D) 1–4 of the murine OSMR receptor were fused to D2–3 of murine gp130 and C-terminally Fc- and HA-tagged. , , Figure generated with BioRender. b Outline of the in vivo anti-OSMR-FP treatment: Intraperitoneal injections (6 µg/g body weight) were administered every two days from day 7 posttransplantation and maintained for 30 days in Jak2 p.V617F + BM recipients. N = 5 for each treatment group. c , d Hemoglobin (HGB) in PBS-, control peptide-, and anti-OSMR-FP-treated animals one month after treatment ( c ) and over time ( d ). N = 5 for each treatment group. * p < 0.05. The data are presented as the means ± SEMs. e Assessment of GM-CSF levels via bead-based flow cytometry in mice 10 weeks after BM transplantation. * p < 0.05. f Hematoxylin/eosin staining of bone specimens from JAK2 p.V617F + mice treated with control peptide (left) or anti-OSMR-FP (right). g Osteosclerosis score. N ≥ 4. * p < 0.05. Statistical analysis was conducted via the Mann‒Whitney test. The data are presented as the means ± SEMs. h Outline of the in vivo treatment of mice transplanted with Jak2 p.V617F + BM with a rat-derived monoclonal <t>anti-mOSM</t> antibody (αOSM). Intraperitoneal injections started on day 7 posttransplantation and were administered weekly for a total of four injections. N = 4 for each treatment group. i , j Hemoglobin (HGB) ( i ) and white blood cell count (WBC) ( j ) in isotype- vs. αOSM-treated animals, as assessed one month after BM transplantation. N = 4 vs. 4. * p < 0.05. The data are presented as the means ± SEMs. k Evaluation of GM-CSF levels on day 80 posttransplantation via bead-based flow cytometry. * p < 0.05. The data are presented as the means ± SEMs
    Anti Osm Aabs, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+osm/pm40702172-603-4-0
    Average 86 stars, based on 1 article reviews
    anti osm aabs - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Treatment of JAK2 p.V617F + animals with an anti-OSM receptor fusion protein or monoclonal anti-OSM antibody ameliorates polycythemia and osteosclerosis. a Structure of the anti-OSM receptor fusion protein (“anti-OSMR-FP”): the extracellular domains (D) 1–4 of the murine OSMR receptor were fused to D2–3 of murine gp130 and C-terminally Fc- and HA-tagged. , , Figure generated with BioRender. b Outline of the in vivo anti-OSMR-FP treatment: Intraperitoneal injections (6 µg/g body weight) were administered every two days from day 7 posttransplantation and maintained for 30 days in Jak2 p.V617F + BM recipients. N = 5 for each treatment group. c , d Hemoglobin (HGB) in PBS-, control peptide-, and anti-OSMR-FP-treated animals one month after treatment ( c ) and over time ( d ). N = 5 for each treatment group. * p < 0.05. The data are presented as the means ± SEMs. e Assessment of GM-CSF levels via bead-based flow cytometry in mice 10 weeks after BM transplantation. * p < 0.05. f Hematoxylin/eosin staining of bone specimens from JAK2 p.V617F + mice treated with control peptide (left) or anti-OSMR-FP (right). g Osteosclerosis score. N ≥ 4. * p < 0.05. Statistical analysis was conducted via the Mann‒Whitney test. The data are presented as the means ± SEMs. h Outline of the in vivo treatment of mice transplanted with Jak2 p.V617F + BM with a rat-derived monoclonal anti-mOSM antibody (αOSM). Intraperitoneal injections started on day 7 posttransplantation and were administered weekly for a total of four injections. N = 4 for each treatment group. i , j Hemoglobin (HGB) ( i ) and white blood cell count (WBC) ( j ) in isotype- vs. αOSM-treated animals, as assessed one month after BM transplantation. N = 4 vs. 4. * p < 0.05. The data are presented as the means ± SEMs. k Evaluation of GM-CSF levels on day 80 posttransplantation via bead-based flow cytometry. * p < 0.05. The data are presented as the means ± SEMs

    Journal: Signal Transduction and Targeted Therapy

    Article Title: Oncostatin M induced by STAT5-activating oncogenes promotes disease progression in hematologic malignancies

    doi: 10.1038/s41392-025-02491-6

    Figure Lengend Snippet: Treatment of JAK2 p.V617F + animals with an anti-OSM receptor fusion protein or monoclonal anti-OSM antibody ameliorates polycythemia and osteosclerosis. a Structure of the anti-OSM receptor fusion protein (“anti-OSMR-FP”): the extracellular domains (D) 1–4 of the murine OSMR receptor were fused to D2–3 of murine gp130 and C-terminally Fc- and HA-tagged. , , Figure generated with BioRender. b Outline of the in vivo anti-OSMR-FP treatment: Intraperitoneal injections (6 µg/g body weight) were administered every two days from day 7 posttransplantation and maintained for 30 days in Jak2 p.V617F + BM recipients. N = 5 for each treatment group. c , d Hemoglobin (HGB) in PBS-, control peptide-, and anti-OSMR-FP-treated animals one month after treatment ( c ) and over time ( d ). N = 5 for each treatment group. * p < 0.05. The data are presented as the means ± SEMs. e Assessment of GM-CSF levels via bead-based flow cytometry in mice 10 weeks after BM transplantation. * p < 0.05. f Hematoxylin/eosin staining of bone specimens from JAK2 p.V617F + mice treated with control peptide (left) or anti-OSMR-FP (right). g Osteosclerosis score. N ≥ 4. * p < 0.05. Statistical analysis was conducted via the Mann‒Whitney test. The data are presented as the means ± SEMs. h Outline of the in vivo treatment of mice transplanted with Jak2 p.V617F + BM with a rat-derived monoclonal anti-mOSM antibody (αOSM). Intraperitoneal injections started on day 7 posttransplantation and were administered weekly for a total of four injections. N = 4 for each treatment group. i , j Hemoglobin (HGB) ( i ) and white blood cell count (WBC) ( j ) in isotype- vs. αOSM-treated animals, as assessed one month after BM transplantation. N = 4 vs. 4. * p < 0.05. The data are presented as the means ± SEMs. k Evaluation of GM-CSF levels on day 80 posttransplantation via bead-based flow cytometry. * p < 0.05. The data are presented as the means ± SEMs

    Article Snippet: Another cohort of mice received treatment with a rat-derived monoclonal anti-mOSM antibody (MAB4951; R&D Systems, Minneapolis, MN, USA) at a dose of 1 μg/g body weight or a corresponding rat IgG 2B (clone 823157, R&D) starting one week after transplantation by weekly i.p. injection.

    Techniques: Generated, In Vivo, Control, Flow Cytometry, Transplantation Assay, Staining, Derivative Assay, Cell Counting